||Tannic acid is a novel hERG channel blocker.
||AMG 487 is a potent and selective antagonist of chemokine (C-X-C motif) receptor 3 (CXCR3) which inhibits the binding of CXCL10 and CXCL11 to CXCR3 with IC50s of 8.0 and 8.2 nM, re
||Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent CXCR4 antagonist and an anti-angiogenic drug that is of potential value in treating choroid neova
||CXCR2-IN-1 has a pIC50 of 9.3 and is a CXCR2 antagonist of the central nervous system penetration agent.
||E6130 may be effective in the treatment of inflammatory bowel disease and is a highly selective CX3CR1 regulator for oral administration.
||Elubrixin inhibits neutrophil CD11b upregulation (IC50 of 260.7 nM) and shape change (IC50 of 310.5 nM). Elubrixin can be used for inflammatory diseases such as inflammatory bowel
||NUCC-390 is a selective agonist of small-molecule CXCR4 receptor.
||NUCC-390 dihydrochloride is selective agonist of small-molecule CXCR4 receptor.
||Reparixin L-lysine salt
||Reparixin L-lysine salt is an allosteric chemokine receptor 1/2 (CXCR1/2) activation inhibitor.
||Motixafortide (BKT140 4-fluorobenzoyl) is an antagonist of CXCR4 (IC50: 1 nM).
||Motixafortide is an antagonist of CXCR4 with IC50 of ～1 nM. It induces the apoptosis of AML blasts by down-regulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 exp
||SB-265610 is a nonpeptide and allosteric CXCR2 antagonist. SB-265610 blocks rat cytokine-induced neutrophil chemoattractant-1 (CINC-1)-induced calcium mobilization and neutrophil c
||SCH 563705 is an effective and orally available CXCR2 and CXCR1 antagonist (IC50s: 1.3 nM, 7.3 nM and Kis of 1 and 3 nM, respectively).
||SRT3190 is an antagonist of CXCR2.
||USL311 is a CXCR4 receptor antagonist which prevents the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4. USL311 inhibits CXCR4 activation and decreases prolife
||WZ811 is a novel and effective small molecular CXCR4 antagonist (EC50: 0.3 nM).
||Plerixafor, a chemokine receptor antagonist, blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4.
||Plerixafor 8HCl (AMD3100 8HCl)
||AMD 3100 octahydrochloride blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bo
||ITIC-4F has broad applicability in high-efficiency binary and ternary single-junction as well as tandem polymer solar cells (PSCs).ITIC-4F is an indacenodithienothiophene (IDTT)-ba
||ITIC has a superior thermal stability and undergoes a glass-crystal transition considerably below its high Tg of 180 °C. ITIC, non-fullerene acceptor, is an indacenodithienothioph
||SB225002 is a potent and selective CXCR2 antagonist inhibiting interleukin IL-8 binding to CXCR2.
||AMD-070 hydrochloride is a CXCR4 antagonist, is useful for Anti HIV.
||UNBS-5162 is a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers.
||SRT3109 is a CXCR2 ligand used in the treatment of chemokine mediated diseases and conditions.
||Arteether is a new, fast-acting antimalarial drug.
||Baohuoside I is a component of Epimedium koreanum, exhibits anti-inflammatory activity and anti-osteoporosis activities.
||MSX-122 is a novel small molecule and partial CXCR4 antagonist, with potent inhibition of CXCR4/CXCL12 actions(IC50 = 10 nM).
||MSX-127 elicites positive response in peptide CXCR4.
||MSX-130 is CXCR4 Antagonist.
||Reparixin is a potent inhibitor of both CXCL8 receptors CXCR1/2, it inhibits weakly CXCR2-mediated cell migration (IC50=100 nM), whereas it strongly blocks CXCR1-mediated chemot
||Danirixin is a potent antagonist of CXCR2 that inhibits IL-8 binding to CXCR2 (IC50: 12.5 nM).
||LIT-927 is an orally active CXCL12 neutraligand (Ki: 267 nM for CXCL12 binding to CXCR4).
||JMS-17-2 is a potent and selective antagonist of CX3CR1( IC50 : 0.32 nM).
||ATI-2341, pepducin targeting the C-X-C chemokine receptor type 4 (CXCR4), is an allosteric agonist activating the inhibitory heterotrimeric G protein (Gi) to promote inhibition of
||Navarixin(SCH527123) is a novel, selective CXC chemokine receptor 2(CXCR2) antagonist that inhibits neutrophil activation and modulates neutrophil trafficking in animal models, cha
||TAK-779 is an antagonist of chemokine receptor 5 (CCR5), CCR2b, and CXC chemokine receptor 3 (CXCR3).
||AZD-5069 is an chemokine receptor 2 antagonist (CXCR2; IC50 = 0.79 nM).
||SX-682 is a potent, selective and orally bioavailable inhibitor of CXCR1/2 ,has the potential to treat castration-resistant prostate cancer.
||Vestitol has antioxidation, anti-inflammatory and antimicrobial activities, it can strongly act in a low dose and concentration and have a promising potential to be applied in the
||FC131 TFA is an antagonist of CXCR4 that inhibits the binding of [125I] -sdf-1 to CXCR4(IC50 : 4.5 nM ), and has anti-hiv activity.
||Balixafortide TFA (POL6326 TFA) is a selective, well-tolerated peptidic CXCR4 antagonist (IC50 < 10 nM). It shows 1000-fold selective for CXCR4 than a large panel of receptors incl
||Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 < 10 nM and it is also a potent hematopoietic stem and progenitor cell (HSPC)
||Mavorixafor (AMD-070) is a selective and orally available CXCR4 antagonist (IC50: 13 nM against CXCR4 125I-SDF binding) and also inhibits the replication of T-tropic HIV-1 (NL4.3 s